Loading...
Market
Highest Growth Division of AstraZeneca by 2025
5
Resolution / Starting Odds
Oncology • 33%
Biopharmaceuticals • 33%
Rare Diseases • 33%
AstraZeneca financial statements or earnings reports
Story
AstraZeneca Targets $80 Billion Revenue by 2030 with 20 New Medicines
May 21, 2024, 07:19 AM
AstraZeneca has set an ambitious target to nearly double its revenue to $80 billion by 2030. This goal is driven by the planned launch of 20 new medicines and growth in its existing oncology, biopharmaceuticals, and rare disease portfolio. CEO Pascal Soriot aims to cement his legacy at the British drugmaker with this significant revenue target. The new target surpasses analyst forecasts and reflects AstraZeneca's confidence in its pipeline expansion and sustained growth post-2030. The company also expects double-digit growth in its oncology division.
View original story
Similar markets
Oncology • 25%
Biopharmaceuticals • 25%
Rare diseases • 25%
Other • 25%
Amgen outperforms AstraZeneca • 33%
AstraZeneca outperforms Amgen • 33%
Both perform similarly • 34%
Less than $500 million • 33%
$500 million to $1 billion • 33%
Greater than $1 billion • 34%
Drug A • 25%
Drug B • 25%
Drug C • 25%
Drug D • 25%
0-5 • 20%
6-10 • 20%
11-15 • 20%
16-20 • 20%
More than 20 • 20%
Asia-Pacific • 33%
North America • 33%
Europe • 34%
